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Abstract
Transition zone biopsies have been found to increase the
detection rates of cancer of the prostate in patients with
negative digital rectal examination. There are however
no data available whether the higher biopsy rate is asso-
ciated with greater morbidity. The present study was
therefore designed to evaluate the complication rate of
extended sextant biopsy. In this prospective study, 162
consecutive patients who presented for prostatic evalua-
tion were included. After starting prophylactic antibiotic
treatment 48 h prior to the procedure, transrectal ultra-
sound-guided core biopsies were obtained from each
lobe: three each from the peripheral zone (apex, mid-
zone and base) and two from the transition zone of each
prostatic lobe. In all patients a questionnaire was ob-
tained 10–12 days after the procedure. Major complica-
tions occurred in 3 patients. In 2 of the 3 cases major
macroscopic hematuria was treated by an indwelling
catheter for 1 or 2 days and 1 patient developed fever
138.5°C for 1 day. Minor macroscopic hematuria was
present in 68.5% of the patients. In 17.9% of these cases,
the hematuria lasted for more than 3 days. Hematosper-
mia was observed in 19.8% and minor rectal bleeding
occurred in 4.9%. Ten-core biopsies did not lead to an
increase in adverse effects or complications when com-
pared to the results of sextant biopsies reported in the
literature.
Copyright © 2001 S. Karger AG, Basel
Introduction
The diagnosis and treatment of prostate cancer (CaP)
requires histological proof. Ultrasound-guided systematic
sextant biopsy of the prostate became the standard proce-
dure for the histological confirmation of CaP. However,
in PSA screening studies there is a high rate of patients
without the confirmation of a CaP (65.6–82.1% [1, 2]). In
these patients a second set of sextant biopsies may be per-
formed to rule out CaP. Keetch et al. [3] could show that
in serial prostatic biopsies, 79% of CaP are detected with
the first set of biopsies, another 16.6% with the second
and only 4.4% with further prostatic biopsies. According
to Keetch et al. [3], a total of 95.6% of CaP can be
detected with two sets of prostatic biopsies. For these rea-
sons, some authors [4, 5] advocate a higher number of
Hodge et al. [15], 1989
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biopsy cores expecting an improvement in the detection
rate especially in large prostate glands. Different proposi-
tions have been made such as a five-region biopsy, taking
far lateral biopsies or taking an individualized number of
biopsy cores depending on the patient’s age and the size of
his prostate. Also, the concept of taking additional transi-
tion zone biopsies has been discussed, as McNeal et al. [6]
could show that more than 20% of CaP originate in the
transition zone only. Reissigl et al. [7] recently confirmed
the data of McNeal et al. [6] (28% tumors originated in
the transition zone only and would not have been detected
by standard sextant biopsy). However, the rate of compli-
cations by performing additional biopsies has to be taken
into consideration, as the biopsy procedure is performed
in 65.6–82.1% on healthy men. In the following study, a
ten-core biopsy protocol, including four biopsies from the
transition zone – taken as a model for an extended biopsy
protocol – was therefore evaluated regarding the compli-
cation rate. In all patients, a questionnaire was obtained
relating to complications and personal discomfort.
Materials and Methods
Between September 1997 and June 1998, men who were referred
for prostate biopsy were admitted to this prospective study after
informed consent. Indications for prostate biopsy were an elevation
in the serum PSA and/or a digital rectal examination (DRE) suspi-
cious for CaP. A total of 162 consecutive men was evaluated. None of
the patients had a history of open or transurethral prostate surgery or
prior radiation therapy. In all cases, DRE was performed and classi-
fied as benign, benign enlargement or suspicious. For prophylactic
antibiotic treatment, ciprofloxacin (2 ! 250 mg b.d.) was adminis-
tered for 5 days, beginning 2 days before the procedure. Men with a
known bleeding tendency were prepared according to the underlying
disorder. Patients with urinary tract infections had their procedure
postponed and received antibiotics corresponding to urinary culture
and sensitivity testing. Careful counseling relative to the possible
complications was carried out with special emphasis on the clinical
importance of infectious side effects and the need for immediate
treatment. Both oral and written consent was obtained. All men
underwent real time transrectal ultrasound using a 7.5-MHz biplanar
ultrasound probe (Siemens Versa®). Core biopsies were obtained by
an automatic biopsy device (BioptyGun®). From each lobe, five
cores were taken: three ultrasound-guided cores from the peripheral
zone (apex, mid-zone and base) and two from the transition zone. All
tumors were classified according to the TNM classification of 1997
[8].
The clinical intra- and perioperative complications were docu-
mented. All patients were followed until complications disappeared.
Ten to12 days after the procedure a urinalysis was done. At the same
time, a questionnaire was given to all the patients. The questionnaire
related to clinical hematuria, hematospermia, rectal bleeding, fever,
pain during the procedure and later discomfort. One of the objectives
of the questionnaire was to determine the length of post-procedural
discomfort following transrectal biopsy. The distribution of parame-
ters was assessed using the Mann-Whitney test.
Results
Patient age ranged from 37 to 79 years (mean 63.4).
Serum PSA levels were elevated in 141 patients (PSA
64 ng/ml; Abbott AxSym enzyme immunoassay). The
mean PSA level was 13.5 ng/ml with a range from 0.4 to
210.0 ng/ml. DRE was suspicious for CaP in 66 patients.
Table 1. Influence of the number of biopsies in bleeding complications after transrectal biopsy of the prostate
Author, year Patients Cores Hematuria
%
Rectal
bleeding, %
Hemato-
spermia, %
251 mean 6.2 NR 1.2 NR
Vallencien et al. [16], 1989 167 1–2 25 12 3
Torp-Pedersen et al. [17], 1989 138 2–3 37 9.4 5
Gustafsson et al. [18], 1990 145 2–4 39.3 NR 46
Collins et al. [11], 1993 89 66 58 37.1 28.1
Aus et al. [13], 1993 391 1–5 13 2.8 9
Clements et al. [19], 1993 80 ^5 20 7.5 11.3
Hammerer and Huland [20], 1994 651 6 14 2 6
Niesel et al. [10], 1995 76 6 48 4 28
Enlund and Varenhorst [12], 1997 415 1–8 (mean 4) 49.6 21.7 NR
Rietbergen et al. [2], 1997 1,687 6–7 23.6a 1.7 45.3
Present series, 2000 162 10 17.9a 4.9 19.8
NR = Not reported.
a Hematuria for more than 3 days.
Kilner et al. [21], 1995
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From each of the 162 patients, ten-core biopsies were
obtained. In all but 1 patient, the biopsies were performed
without general anesthesia on an outpatient procedure.
The patients reported no or only minimal discomfort dur-
ing the procedure. Histological examination revealed the
diagnosis of CaP in 52 of the 162 patients (32.1%). Tumor
stages were classified as T1c (n = 10), T2 (n = 24), T3 (n =
15), and T4 (n = 3) according to the 1997 TNM classifica-
tion [8]. Of the T2 cancers (according to the TNM classifi-
cation) 15 had a positive DRE while 9 had a normal DRE
but a suspicious lesion in TRUS.
The complications of the procedure are specified in
tables 1–3. In 2 cases, severe macroscopic hematuria had
to be treated by an indwelling catheter for 1 or 2 days. No
bleeding necessitating blood transfusion occurred. Minor
(macroscopic) hematuria was present in 68.5% of the
patients; in 17.9% of these cases hematuria persisted for
more than 3 days (table 2) and 4.9% of the patients had
hematuria for more than 7 days. Thirty-two patients
developed hematospermia (19.8%). Minimal rectal bleed-
ing was noted in 4.9%. Surgical intervention was not
required in any case. Urinary retention did not occur,
Table 2. Duration of hematuria after trans-
rectal biopsy of the prostate
Duration of hematuria n %
0 51 31.5
1 day 37 22.8
2–3 days 45 27.8
4–7 days 21 13.0
78 days 8 4.9
while 24 patients (14.8%) reported a temporarily ob-
structed micturition. Infectious complications such as
septicemia (n = 0) or fever (138.5°C; n = 1) were rare.
Ten to 12 days after this procedure, no patient had uri-
nary tract infection (positive urine culture). The analysis
of complications did not reveal significantly more compli-
cations in the group of patients with CaP than in men with
a benign histology.
Discussion
PSA screening for prostate cancer led to a rapid
increase in the numbers of prostate biopsies performed in
the last years. For 1998, Landis et al. [9] estimated
184,500 new cases of CaP in the United States based on
the Surveillance, Epidemiology and End Results data of
the National Cancer Institute. Regarding the detection
rate of the screening studies already mentioned above, in
the United States the number of prostate biopsies per-
formed can be estimated to be two- to threefold higher.
This fact leads to the question of the morbidity of this
diagnostic procedure, especially if the number of cores
taken is increased. Although important improvements
were made in the biopsy technique, e.g. the use of Tru-Cut
needles instead of Silverman needles, spring-loaded biop-
sy guns instead of hand proceeded needles and ultrasound
instead of digitally guided biopsies, severe complications
of prostatic biopsy do occur.
In the present series, severe bleeding was found in 2 of
162 patients (1.2%) which could be resolved by a short-
term indwelling catheter. Similar results were reported by
Niesel et al. [10], who performed sextant biopsy and had
to insert indwelling catheters in 2.6% of their patients.
Table 3. Influence of prophylactic
antibiotic treatment and time of first
application on the rate of clinical infection
in patients with six or more biopsy cores
Author, year Patients Prophylactic
antibiotic
treatment
Time of first
application
hours before
biopsy
Fever
%
Septi-
cemia
%
98 N – 9 NR
Hodge et al. [15], 1989 251 Y 1 0.8 NR
Collins et al. [11], 1993 89 Y 1 4.5 0
Hammerer and Huland [20], 1994 372 Y 1 0.5 NR
Rietbergen et al. [2], 1997 1,687 Y 2 4.2 0.2
Niesel et al. [10], 1995 76 Y 24 9.0 0
Sieber et al. [14], 1997 4,439 Y 24 0.07 0
Present series, 2000 162 Y 48 0.6 0
Y = Yes; N = no; NR = not reported.
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Transfusion as a result of a major bleeding complication
was never necessary after ten-core biopsies were taken.
However, 17.9% of the patients reported minor bleeding
such as hematuria for more than 3 days. This is in accor-
dance with other studies on sextant biopsies, where hema-
turia was present in 14–58% of patients biopsied (ta-
ble 1).
Theoretically, the number of cores taken should in-
fluence the rate of complications, as the risk for bleeding
or infection should be the same for every single core. So
the complication rate should increase with each addition-
al core taken. Table 1 shows the results of studies with
different numbers of cores taken and the reported bleed-
ing complications. In contrast to the theoretical assump-
tion, there is no obvious recognizable trend for more com-
plications with increasing numbers of core biopsies (ta-
ble 1). Hematuria ranges from 13 to 58%, the same wide
range exists for rectal bleeding (1.2–37.1%) and hemato-
spermia (3–46%). Besides other reasons, this may be due
to different study designs and ultrasound probes used.
Manufacturers provide ultrasound probes of various
sizes, biopsy angles and needle sleeves. The angle for the
biopsy may in so far represent a potential risk factor, as
narrow angles may result in a higher rate of bladder perfo-
rations in biopsies taken near the bladder neck. Further-
more, the needle sleeves may hold a possible risk for
mucosal injury of the rectum.
Other important points are the infectious complica-
tions of transrectal prostatic biopsy. In this series, clinical
infections were rarely seen, which is probably due to the
antibiotic regimen of 5 days beginning 2 days prior to the
procedure. So the rate of patients with fever (0.6%) was
rather low, and no additional risk by the extended biopsy
could be found in comparison to the literature.
The questionnaire filled out by all patients showed that
discomfort as well as hematuria and hematospermia may
last longer than 8 days in a considerable number of
patients. It is therefore important to inform the patients
prior to the treatment.
In conclusion, the extension of six- to ten-core biopsies
did not lead to a recognizable increase in adverse effects
or complications when compared with the data of sextant
biopsy reported in the literature.
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